Articles On Immutep (ASX:IMM)

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

In October, the Chinese government released its intellectual proprietary (IP) patents strategy paper, listing its main goals for the next five years. Part of that plan is to double the foreign “high value” patents from the current 40,000 to...

Intelicare nabs MercyCare contract for its AI sensor tech Telix scores TGA approval for prostate cancer imaging product MGC receives Israeli approval for COVID treatment dosing study   Intelicare Holdings (ASX:ICR) Intelicare jumped 35.4...

The Immutep Ltd (ASX: IMM) share price is climbing today after the biotechnology company announced it has secured a new patent. At the time of writing, Immutep shares are edging 1.7% higher to 59.5 cents. In the last month, its shares have...

Immutep (IMM) is granted a new patent by the Chinese Patent Office for its lead product candidate, eftilagimod alpha The new patent relates to methods of use of efti in combination with a chemotherapy agent to treat cancer The new Chinese...

Shares in Immutep (IMM) open green after the company announced positive feedback from European regulators around its lead anti-cancer drug candidate Immutep says the European Medicines Agency (EMA) supported IMM’s continued development of...

Nasdaq at all time high Tech stocks rallied in New York overnight, pushing up the Nasdaq composite index by 1.39% to its highest level ever. The Dow Jones rose by 0.68% and S&P 500 by 0.98% (also at all-time highs), capping off a good d...

Shares in clinical stage biotechnology company Immutep Ltd (ASX: IMM) are inching higher in afternoon trading, up 2.5% to 62 cents apiece. Immutep’s share price has been on the move amid the release of its annual report today, in which...

MoneyTalks is Stockhead’s regular recap of the stocks, sectors and trends that fund managers and analysts are looking at right now and in this edition we’re looking at big biotechs. Today we hear from James McDonald, portfolio manager of Pe...

ShareCafeThe Week that Was – October 11-16, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier to do so...

ShareCafeImmutep Taking the Fight to Cancer In May 2021, Corporate Connect analyst Marc Sinatra published a comprehensive research report on ASX-listed biotech Immutep Ltd (ASX: IMM). So impressed was he with IMM that Corporate Connect felt...

Global stocks sell off as bond yields rise All three US stock market benchmark indexes fell sharply overnight, as the 10-year benchmark US Treasury yield continues its rapid climb. The 10-year yield was up by 6 basis points to 1.54%, its hi...

The Immutep Ltd (ASX: IMM) share price is pushing higher again on Monday despite the market decline. At the time of writing, the biotechnology company’s shares are up almost 4% to 55 cents. This means the Immutep share price is now up 25%...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays.   Theme of the week The Healthc...

ShareCafeThe Week that Was – August 30-September 3, 2021 We at ShareCafe understand you are busy and may not have been left with enough time to keep up with the quality content we’ve been bringing you throughout the week. To make it easier...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX powerplays. Theme of the week The Healthcar...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

Small-cap biotech stock Immutep [ASX:IMM] is on the up today. Shares are currently trading 7.92% higher at time of writing. Climbing higher thanks to some positive news in relation to the company’s ongoing clinical trials. The post 7% Gain...

Small-cap biotech stock Immutep Ltd [ASX:IMM] is on the up today. The IMM share price is currently trading 7.92% higher at time of writing... The post 7% Up For Immutep Share Price — Progresses Clinical Trials (ASX:IMM) appeared first on M...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is off its intraday lows but still trading lower. At the time of writing, the benchmark index is down 0.3% to 7,513.5 points. Four ASX shares that are not letting that hold them back...

The Immutep Ltd (ASX: IMM) share price is gaining today following news of the company’s Two ACTive Immunotherapies (TACTI-002) trial. Recruitment for the trial’s stage 2 of part B is now officially complete. Right now, the Immutep share pr...

ShareCafeImmutep Leading the development of immunotherapy for cancer and autoimmune diseases   Fund manager James McDonald at the Pengana High Conviction Equities Fund provides insight into some of the current opportunities arising for the...

Immutep (ASX:IMM) has announced that its Chinese partner for eftilagimod alpha (efti), EOC Pharma, is planning to expand its clinical trial pipeline for the investigative immunotherapy.

The CAR T-cell therapy (Chimeric Antigen Receptor) has been billed as a radical new way to cure cancer. But since the US FDA approved the first cell-gene therapy to treat leukemia in 2018, the technology has not really caught on in the main...

The ASX 200 closed at 7,488 points which was 0.04% down from yesterday but up 0.37% from last Friday. The ASX Emerging Companies Index lost 0.57% to close at 2,285 points. The best sector was industrials which gained 1.07%. Tech and consume...

Highlights Emyria has entered into a Master Services Agreement with Calvert Labs, a leading North American preclinical contract research organisation. Advanced Human Imaging announced the public filing of a registration statement with...

The Immutep Ltd (ASX: IMM) share price has stepped into the green from the opening of trade on Friday. Immutep shares are on the move as the company announced it had been granted a Chinese patent on one of its antibody molecules. Let’s i...

Wall Street snaps three-day gain streak All three US stock market indexes fell last night, and snapped their streak of gains in the previous three days. The Dow Jones fell by 0.54%, S&P500 by 0.58%, and the tech heavy Nasdaq by 0.64%. F...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

Summary  Latitude Group Holdings has cracked a deal for fintech Symple to accelerate business growth. Telstra Health has signed a pact to acquire MedicalDirector to support its vision of becoming a leading partner to the healthcare sec...

Trading Places is Stockhead’s recap of the buys and sells of ASX small cap shares by fund managers and other famous investors over the last fortnight. Specifically, Stockhead tracks substantial shareholder movements, being shareholders hold...

Summary Emyria has signed a deal with the University of Western Australia (UWA) to develop a novel psychedelics pipeline. Pharmaxis’ anticancer drug PXS-5505 shows positive results in the pre-clinical liver cancer model. Immutep updat...

ASX 200 health stocks index (XHJ) rose by 0.23% this morning, compared to the broader index which rose by 0.11%. Micro cap medical device company dorsaVi (ASX:DVL) took the limelight this morning, jumping by 12% after saying that it has ext...

Immutep Ltd (ASX: IMM) shares are lifting on Thursday morning following an clinical trial update from the company. At the time of writing, the Immutep share price is trading 2% higher at 51 cents. Below we take a look at the ASX healthcare...

Immutep (ASX:IMM) has announced that the first patient has been enrolled and safely dosed in INSIGHT-003 study that includes its LAG-3 investigative immunotherapy.

Wall Street mixed on Fed’s statement US stock markets were mixed overnight, after the US Fed Vice Chair said he anticipates rates to increase by 2023. “Given this outlook and so long as inflation expectations remain well anchored at the 2%...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

ShareCafeInstitutions Support Immutep Capital Raising Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) is pleased to announce it has completed the second tranche of its institutional placement (Placement), details of wh...

Investor funds continue flowing into ASX listed biotechnology shares this year, with a total of almost $485 million of capital raised this year to date. Adding the flurry of initial public offerings (IPO) undertaken in the biotech domain,...

Immutep (ASX:IMM) has announced that its share purchase plan has closed with the company receiving total funds of A$7,175,720 that exceeds the amount originally sought.

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Healthcare is a constantly changing industry in which you may be asking yourself if your investments are up to date. While the healthcare sector underperformed the S&P/ASX 200 Index (ASX: XJO) in FY21, there were still some ASX-listed...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Immutep (ASX:IMM) and Opthea (ASX:OPT) both received the blessing of the FDA for their clinical trial ambitions this morning, with Immutep winning approval to start a clinical trial and Opthea winning Fast Track Designation.   Opthea gets F...

Shares in Immutep Ltd (ASX: IMM) are soaring today following news of its latest drug trial. Currently, the Immutep share price is trading at 56 cents, 5.6% higher than its previous close. The biotechnology company has received approval fro...

Australian immunotherapy company Immutep (ASX:IMM) has announced a $60 million capital raise and approval for a phase one clinical trial of its lead investigative candidate as part of a triple combination for the treatment of variou...

Summary The ASX dropped over 2% to hit intraday low of 7,216.60, led by sharp sell-off in financials, energy, and industrial stocks. The market sentiments were dented by the US Fed official comment that the central bank might raise int...

The Immutep Ltd (ASX: IMM) share price has returned from its trading halt and is sinking lower on Monday morning. At the time of writing, the biotechnology company’s shares are down 16% to 51.5 cents. Despite this decline, the Immutep shar...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...